IL6 and rheumatoid arthritis: Moreover, the disproportional reduction in CRP levels in comparison with clinical measures of inflammation is a well-known phenomenon in RA patients treated with anti IL6 and it has been observed even in those treated with JAK inhibitors, due to the intracellular effect of JAK inhibitors on the IL6 pathway (28).